Gut, Bone, and Immune Health
How kefir's unique microbial cultures support digestion, reduce inflammation, and strengthen bones
Kefir is a fermented milk drink made by culturing dairy with kefir grains — a symbiotic community of bacteria and yeasts unlike any other fermented food. It contains a broader and more diverse range of live microorganisms than yogurt, and those microbes do measurable things: they shift the gut microbiome [1], reduce markers of inflammation [2], and help people who cannot normally digest milk tolerate it comfortably [5]. It is one of the most well-researched fermented foods, with clinical trials supporting its role in gut health, bone metabolism, and immune function.
What Makes Kefir Different from Yogurt
Yogurt typically contains two to four bacterial strains added during manufacturing. Kefir grains — the irregular, cauliflower-like clusters used to ferment kefir — harbor dozens of bacterial species plus several yeasts, all living together in a stable, self-perpetuating community. When those grains ferment milk, they produce the same microorganisms along with organic acids, bacteriocins (natural antimicrobials), and bioactive peptides derived from the partial digestion of milk proteins.
This complexity matters because different microbial species colonize different niches in the gut, produce different metabolites, and interact with the immune system in different ways. A 2023 crossover trial found that traditionally fermented kefir — made with natural grain cultures — significantly reduced LDL cholesterol, CRP, and the adhesion molecules ICAM-1 and VCAM-1, while commercially produced kefir (often made from starter cultures rather than full grains) did not show the same benefits and actually increased TNF-α in some participants [6]. The microbial community, not just the presence of probiotics, appears to drive the outcome.
Gut Health and the Microbiome
In people with metabolic syndrome, 12 weeks of daily kefir reduced fasting insulin, insulin resistance (HOMA-IR), and pro-inflammatory cytokines including TNF-α and IFN-γ. It also increased the relative abundance of Actinobacteria — a phylum associated with gut lining integrity and metabolic health [1].
In a trial with inflammatory bowel disease patients, 400 mL of kefir per day for four weeks significantly increased Lactobacillus counts in stool, reduced CRP and erythrocyte sedimentation rate in Crohn's disease patients, and improved quality-of-life scores [2]. Bloating scores improved during the final two weeks of the trial.
A 2023 systematic review of 16 randomized controlled trials found the most consistent evidence for kefir's benefit in three areas: reducing oral Streptococcus mutans (a cavity-causing bacterium), supporting eradication of Helicobacter pylori, and improving lipid profiles and blood pressure in adults with dyslipidemia or hypertension [7]. The reviewers noted that 12 of 18 included studies had methodological limitations, so these findings are promising rather than definitive.
Lactose Intolerance
People who cannot digest lactose — estimated at 68% of the global adult population — often tolerate kefir significantly better than regular milk. In a crossover trial, adults with confirmed lactose maldigestion exhaled 61% less hydrogen gas after drinking kefir versus plain milk (87 vs. 224 ppm×h on breath hydrogen testing). Perceived flatulence was reduced by 54–71% [5].
The mechanism is straightforward: the microorganisms in kefir produce lactase (beta-galactosidase), which pre-digests much of the lactose before the drink is consumed. Additionally, the slow gastric emptying caused by the slightly viscous consistency of kefir gives remaining lactase more time to act in the small intestine. This makes kefir accessible to many people who avoid dairy entirely due to digestive discomfort.
Bone Health
In a six-month double-blind trial in osteoporotic patients, kefir shifted the balance between bone resorption and bone formation more favorably than calcium supplementation alone. The bone resorption marker beta-CTX decreased in patients with higher baseline bone density, and the bone formation marker osteocalcin showed a positive trend at six months in the kefir group [3]. Hip bone mineral density increases were greater in the kefir group than in the calcium-only control group, though the study was small (40 participants) and short enough that larger structural changes are unlikely to be fully captured.
The proposed mechanisms include the role of kefir-derived peptides in modulating osteoclast and osteoblast activity, improved calcium and phosphorus absorption in a more acidic gut environment, and vitamin K2 produced by some strains of bacteria in the fermentation process. See our vitamin K2 page for more on how K2 directs calcium into bone rather than arterial walls.
Immune Modulation
A six-week trial in healthy adults found that 200 mL of kefir per day significantly reduced IL-8 (a pro-inflammatory cytokine) at both three and six weeks, with suppression persisting three weeks after consumption stopped [4]. IL-5 (associated with allergic response) initially rose then declined, and the authors interpreted the pattern as a shift toward a Th1-dominant immune response — a pattern generally associated with reduced allergic and inflammatory reactivity. The study was small (18 participants), so these findings should be treated as preliminary.
Practical Guidance
Plain, traditionally fermented kefir made from whole grains offers the most diverse microbial community. Commercially produced kefir varies considerably — some products are made from defined starter cultures and may not deliver the same benefits. If purchasing commercial kefir, look for products listing multiple bacterial species and genuine Lactobacillus kefiranofaciens or Lactobacillus kefiri on the label.
Homemade kefir from purchased grains is straightforward: add grains to whole milk, cover with cloth, leave at room temperature for 24–48 hours, strain, and refrigerate. The grains reuse indefinitely.
Typical amounts used in clinical trials range from 200 to 400 mL per day. Most people tolerate kefir well; those with severe lactose intolerance or milk protein allergy should start with small amounts or consider water kefir, which ferments sugar water or coconut water with a related but distinct set of grains.
See our fermented foods page for broader context on how fermentation transforms food, and our probiotics page for guidance on probiotic strains and clinical evidence.
Evidence Review
Gut Microbiome and Metabolic Health
Bellikci-Koyu et al. (2019, PMID 31487797) conducted a 12-week parallel-group RCT in 22 adults with metabolic syndrome. The kefir group consumed 180 mL/day. Within-group analysis showed significant reductions in fasting insulin (p ≤ 0.05), HOMA-IR (p ≤ 0.05), TNF-α (p ≤ 0.05), and IFN-γ (p ≤ 0.05), along with decreased systolic and diastolic blood pressure. Relative abundance of Actinobacteria increased significantly (p = 0.023). Between-group differences did not reach statistical significance, which the authors attributed to the small sample size and the parallel (rather than crossover) design, which reduces power. The study is limited by short duration and reliance on within-group changes.
Yilmaz et al. (2019, PMID 30662004) enrolled 45 IBD patients (25 kefir, 20 control) in a 4-week trial using 400 mL/day. In Crohn's disease patients, ESR (erythrocyte sedimentation rate) and CRP decreased significantly (p < 0.05) and hemoglobin increased. Lactobacillus counts in stool increased significantly (p = 0.001 in ulcerative colitis; p = 0.005 in Crohn's). Bloating scores improved over the final two weeks (p = 0.012), and quality-of-life scores (IBDQ) improved (p = 0.032). The control group received no placebo, introducing potential bias.
Systematic Evidence Base
Kairey et al. (2023, PMID 35913411) systematically reviewed 18 publications from 16 RCTs of kefir. The highest-quality evidence supported: reduction of oral Streptococcus mutans and dental caries risk; improved H. pylori eradication rates when kefir was added to standard antibiotic therapy; and improvements in dyslipidemia and hypertension in adults. However, 12 of the 18 studies had high risk of bias by Cochrane criteria, and only 5 assessed safety outcomes. The reviewers concluded that current evidence is insufficient to make clinical recommendations, and called for larger, well-designed trials.
Lipid and Inflammation Profiles
Bourrie et al. (2023, PMID 37224566) conducted a randomized crossover trial in 21 healthy males using two 4-week treatment periods (traditional kefir vs. commercial kefir) separated by a 4-week washout. Traditional kefir significantly reduced LDL cholesterol, ICAM-1, and VCAM-1 versus baseline (p < 0.05). Compared to commercial kefir, traditional kefir produced significantly greater reductions in IL-8, CRP, VCAM-1, and TNF-α (all p < 0.05). Commercial kefir unexpectedly increased TNF-α. The study demonstrates that microbial community composition — not merely the label "kefir" — determines health outcomes. Limitations: small sample, male-only, pilot design.
Bone Metabolism
Tu et al. (2015, PMID 26655888) conducted a 6-month double-blind RCT in 40 osteoporotic patients randomized to kefir-fermented milk or calcium-supplemented control milk. In patients with T-scores above −1 (less severe bone loss), beta-CTX (C-terminal telopeptide, a bone resorption marker) decreased significantly at 3 months in the kefir group. Osteocalcin (a bone formation marker) showed net positive change at 6 months in the kefir group versus negative change in controls. Hip BMD increases were numerically greater in the kefir group, though statistical significance for group differences was not consistently reached. Parathyroid hormone rose in both groups, likely reflecting the study's calcium manipulation rather than kefir specifically. Study limitations: small sample, single center, short duration relative to meaningful BMD change timelines.
Lactose Digestion
Hertzler and Clancy (2003, PMID 12728216) tested 15 adults with confirmed lactose maldigestion in a randomized block design. Breath hydrogen AUC after 500 mL of plain milk was 224 ± 39 ppm·h. After plain kefir it was 87 ± 37 ppm·h (p < 0.001), a 61% reduction. Flavored kefir reduced it to 156 ± 26 ppm·h. Perceived flatulence severity decreased by 54–71% across kefir and yogurt conditions. Abdominal pain and diarrhea were negligible. This is the most rigorously designed human trial on kefir and lactose tolerance, though it predates modern microbiome analysis, which may have provided mechanistic detail.
Immune Function
Adiloglu et al. (2013, PMID 23621727) measured serum cytokines in 18 healthy adults (age 20–40) before, during, and after 6 weeks of 200 mL/day kefir consumption. IL-8 decreased significantly at weeks 3 and 6 (p < 0.001) and remained suppressed 3 weeks post-consumption (p = 0.002). IL-5 increased at week 3 (p = 0.01) then fell by week 9 (p = 0.003). TNF-α increased during consumption (p = 0.046). The pattern was interpreted as Th1 polarization, which may reduce Th2-mediated allergic responses. Major limitations: no control group, very small sample, measurement in healthy adults limits clinical translation.
Overall Evidence Assessment
Kefir has more clinical trial evidence than most fermented foods, but the quality is mixed. The most robust findings — lactose tolerance improvement and diverse microbial colonization — are supported by well-designed trials. Evidence for anti-inflammatory effects, bone health, and metabolic benefits is promising but limited by small sample sizes and methodological heterogeneity. The 2023 comparison of traditional versus commercial kefir is an important caution: the health effects attributed to kefir in the literature may not apply uniformly to all products on the market. Traditional, grain-fermented kefir from diverse microbial cultures appears to be the more therapeutically relevant form.
References
- Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled StudyBellikci-Koyu E, Sarer-Yurekli BP, Akyon Y, Aydin-Kose F, Karagozlu C, Ozgen AG, Brinkmann A, Nitsche A, Ergunay K, Yilmaz E, Buyuktuncer Z. Nutrients, 2019. PubMed 31487797 →
- Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trialYilmaz I, Dolar ME, Ozpinar H. Turkish Journal of Gastroenterology, 2019. PubMed 30662004 →
- Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic PatientsTu MY, Chen HL, Tung YT, Kao CC, Hu FC, Chen CM. PLoS One, 2015. PubMed 26655888 →
- The effect of kefir consumption on human immune system: a cytokine studyAdiloglu AK, Gonulates N, Isler M, Senol A. Mikrobiyoloji Bulteni, 2013. PubMed 23621727 →
- Kefir improves lactose digestion and tolerance in adults with lactose maldigestionHertzler SR, Clancy SM. Journal of the American Dietetic Association, 2003. PubMed 12728216 →
- Consumption of kefir made with traditional microorganisms resulted in greater improvements in LDL cholesterol and plasma markers of inflammation in males when compared to a commercial kefir: a randomized pilot studyBourrie BCT, Forgie AJ, Makarowski A, Cotter PD, Richard C, Willing BP. Applied Physiology, Nutrition, and Metabolism, 2023. PubMed 37224566 →
- The effects of kefir consumption on human health: a systematic review of randomized controlled trialsKairey L, Leech B, El-Assaad F, Bugarcic A, Dawson D, Lauche R. Nutrition Reviews, 2023. PubMed 35913411 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.